Latest Gadolinium Stories

The FDA has granted fast track designation to Amag Pharmaceuticals's ferumoxytol for its development as a diagnostic agent for vascular-enhanced magnetic resonance imaging to improve the assessment of peripheral arterial disease in patients with known or suspected chronic kidney disease. If approved for an imaging indication, ferumoxytol could offer an alternative to gadolinium-based contrast agents, which are required to contain a black box warning highlighting the risks of using...

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ferumoxytol for its development as a diagnostic agent for Vascular-Enhanced Magnetic Resonance Imaging (VE-MRI) to improve the assessment of peripheral arterial disease in patients with known or suspected chronic kidney disease (CKD). If approved for an imaging indication, ferumoxytol could offer an alternative to gadolinium-based contrast agents,...

WAYNE, N.J., April 8, 2008 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the company has been awarded a two-year contract by Amerinet, Inc. to make Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R) (iopromide) injection available to members of the Amerinet network. Amerinet is a leading national health care group purchasing organization that serves more than 26,000 acute and non-acute healthcare providers...

HOUSTON, Aug. 11, 2005 -- Researchers at Rice University, the Baylor College of Medicine, the University of Houston and the Ecole Polytechnique Fédérale de Lausanne in Switzerland have created a new class of magnetic resonance imaging (MRI) contrast agents that are at least 40 times more effective than the best in clinical use. The new agents -- dubbed gadonanotubes -- use the same highly toxic metal, gadolinium, that is given to more than a quarter of MRI patients today, but the metal...